Literature DB >> 21681701

Serum C-reactive protein level as a biomarker for differentiation of ischemic from hemorrhagic stroke.

Seyed Ali Roudbary1, Farshid Saadat, Kambiz Forghanparast, Reza Sohrabnejad.   

Abstract

Cerebrovascular accidents rank first in the frequency and importance among all neurological disease. Although a number of studies had shown increased level of the high sensitive C-reactive protein (hs-CRP) in patients with ischemic stroke, the association of increased hs-CRP with various type of stroke especially the assessment hs-CRP level in ischemic and hemorrhagic stroke have not been investigated. In the present study, we assessed the concentration of hs-CRP in patients with documented ischemic and hemorrhagic stroke in the first 24 hours of the onset of symptoms. Thirty-two patients with Ischemic and hemorrhagic stroke were evaluated at neurology department of Poursina Hospital. The presence of baseline vascular risk factors, including hypertension, diabetes mellitus, hypercholesterolemia, obesity, and smoking, was determined. The blood samples were then collected and routine hematology and biochemistry tests were done. hs-CRP levels were determined using a highly sensitive immunonephelometric method. In this cross sectional study, the age of patient varied from 45-85 years (Mean 70.9 ± 9.4). Serum level of hs-CRP in Ischemic patients were 18.92 ± 11.28 and in hemorrhagic group was 2.65 ± 1.7. This relationship was statistically significant (P<0.0001). It might be concluded that hs-CRP might be considered as a usefully adjunct method for the initial diagnosis of the type of stroke.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21681701

Source DB:  PubMed          Journal:  Acta Med Iran        ISSN: 0044-6025


  8 in total

1.  Liquid biopsy markers for stroke diagnosis.

Authors:  Harshani Wijerathne; Malgorzata A Witek; Alison E Baird; Steven A Soper
Journal:  Expert Rev Mol Diagn       Date:  2020-07-05       Impact factor: 5.225

2.  Thrombomodulin and High-Sensitive C-Reactive Protein Levels in Blood Correlate with the Development of Cerebral Infarction Among Asians.

Authors:  Yan Han; Shuai Wu; Qiang Hu; Jian-Qi Xiao; Dong-Mei Wei; Li-Li Liu; Ze-Zhi Li
Journal:  Mol Neurobiol       Date:  2015-07-02       Impact factor: 5.590

3.  Serum protease-activated receptor (PAR-1) levels as a potential biomarker for diagnosis of inflammation in type 2 diabetic patients.

Authors:  Sanjay Goyal; Ankita Sood; Isha Gautam; Soumyadip Pradhan; Puskar Mondal; Gaaminepreet Singh; Ravinder Singh Jaura; Thakur Gurjeet Singh; Raminderpal Singh Sibia
Journal:  Inflammopharmacology       Date:  2022-08-16       Impact factor: 5.093

4.  CRP gene (1059G>C) polymorphism and its plasma levels in ischemic stroke and hemorrhagic stroke in a south Indian population.

Authors:  Satrupa Das; Sitara Roy; Subhash Kaul; Akka Jyothy; Anjana Munshi
Journal:  Inflammation       Date:  2014-10       Impact factor: 4.092

Review 5.  C-reactive protein and long-term ischemic stroke prognosis.

Authors:  Reyna L VanGilder; Danielle M Davidov; Kyle R Stinehart; Jason D Huber; Ryan C Turner; Karen S Wilson; Eric Haney; Stephen M Davis; Paul D Chantler; Laurie Theeke; Charles L Rosen; Todd J Crocco; Laurie Gutmann; Taura L Barr
Journal:  J Clin Neurosci       Date:  2013-08-23       Impact factor: 1.961

Review 6.  Monitoring inflammation (including fever) in acute brain injury.

Authors:  J Javier Provencio; Neeraj Badjatia
Journal:  Neurocrit Care       Date:  2014-12       Impact factor: 3.210

Review 7.  The Clinical Significance and Potential Role of C-Reactive Protein in Chronic Inflammatory and Neurodegenerative Diseases.

Authors:  Ying-Yi Luan; Yong-Ming Yao
Journal:  Front Immunol       Date:  2018-06-07       Impact factor: 7.561

8.  Fisetin Prolongs Therapy Window of Brain Ischemic Stroke Using Tissue Plasminogen Activator: A Double-Blind Randomized Placebo-Controlled Clinical Trial.

Authors:  Limin Wang; Di Cao; Huijun Wu; Hongning Jia; Chaoping Yang; Lihua Zhang
Journal:  Clin Appl Thromb Hemost       Date:  2019 Jan-Dec       Impact factor: 2.389

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.